FDA approves listing of Pfizer biosimilar Zirabev-bvzr
-
Last Update: 2020-06-09
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, Pfizer announced that itThe FDA(http://approved the listing of its biosimilar, Zirabev-bvzrabout Zirabev
Zirabev is a biosimilar to the heavy anticancerdrug(http://bevacizumab, approved for the treatment of five types of cancer:metastatic colorectal cancer;Bevalbezumab and other complex drugs, known as biologics, are made from living cells and are difficult to replicate preciselySo the generic version of the drug is called a biosimilarAs a monoantigen that specifically binds to the vascular endothelial growth factor (VEGF) protein, bevalbezumab interferes with the tumor's bloodsupply(http://by blocking the binding of VEGF to receptors on vascular cells THIS FDA approval is based on a review of comprehensive data on the biosimilars of Zirabev and bevalbeth resistance data show edges the clinical equivalence and non-difference of Zirabev
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
